Evidence map›Paper›PMID 28728577›Full record

ArticleBMC medical research methodology2017

Integrating data from randomized controlled trials and observational studies to predict the response to pregabalin in patients with painful diabetic peripheral neuropathy.

Joe Alexander, Roger A Edwards, Alberto Savoldelli, Luigi Manca, Roberto Grugni, Birol Emir, Ed Whalen, Stephen Watt, Marina Brodsky, Bruce Parsons

Abstract read
In one paragraph

Article in BMC medical research methodology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Joe AlexanderPfizer Inc, 235 E 42nd St, New York, NY, 10017, USA. Joe.Alexander.Jr@pfizer.com.ORCID http://orcid.org/0000-0003-2628-8199
Roger A EdwardsHealth Services Consulting Corporation, 169 Summer Road, Boxborough, MA, 01719, USA.
Alberto SavoldelliFair Dynamics Consulting, srl, Via Carlo Farini, 5, 20154, Milan, Italy.
Luigi MancaFair Dynamics Consulting, srl, Via Carlo Farini, 5, 20154, Milan, Italy.
Roberto GrugniFair Dynamics Consulting, srl, Via Carlo Farini, 5, 20154, Milan, Italy.
Birol EmirPfizer Inc, 235 E 42nd St, New York, NY, 10017, USA.
Ed WhalenPfizer Inc, Eastern Point Rd, Groton, CT, 06340, USA.
Stephen WattPfizer Inc, 235 E 42nd St, New York, NY, 10017, USA.
Marina BrodskyPfizer Inc, 235 E 42nd St, New York, NY, 10017, USA.
Bruce ParsonsPfizer Inc, 235 E 42nd St, New York, NY, 10017, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMore patient-specific medical care is expected as more is learned about variations in patient responses to medical treatments. Analytical tools enable insights by linking treatment responses from different types of studies, such as randomized controlled trials (RCTs) and observational studies. Given the importance of evidence from both types of studies, our goal was to integrate these types of data into a single predictive platform to help predict response to pregabalin in individual patients with painful diabetic peripheral neuropathy (pDPN).

methodsWe utilized three pivotal RCTs of pregabalin (398 North American patients) and the largest observational study of pregabalin (3159 German patients). We implemented a hierarchical cluster analysis to identify patient clusters in the Observational Study to which RCT patients could be matched using the coarsened exact matching (CEM) technique, thereby creating a matched dataset. We then developed autoregressive moving average models (ARMAXs) to estimate weekly pain scores for pregabalin-treated patients in each cluster in the matched dataset using the maximum likelihood method. Finally, we validated ARMAX models using Observational Study patients who had not matched with RCT patients, using t tests between observed and predicted pain scores.

resultsCluster analysis yielded six clusters (287-777 patients each) with the following clustering variables: gender, age, pDPN duration, body mass index, depression history, pregabalin monotherapy, prior gabapentin use, baseline pain score, and baseline sleep interference. CEM yielded 1528 unique patients in the matched dataset. The reduction in global imbalance scores for the clusters after adding the RCT patients (ranging from 6 to 63% depending on the cluster) demonstrated that the process reduced the bias of covariates in five of the six clusters. ARMAX models of pain score performed well (R

conclusionThe combination of cluster analyses, CEM, and ARMAX modeling enabled strong predictive capabilities with respect to pain scores. Integrating RCT and Observational Study data using CEM enabled effective use of Observational Study data to predict patient responses.

Indexed as

AdultAgedAnalgesicsCluster AnalysisDiabetic NeuropathiesFemaleHumansMaleMiddle AgedObservational Studies as TopicOutcome Assessment, Health CarePain ThresholdPregabalinPrognosisRandomized Controlled Trials as TopicAnalgesicsPregabalinAutoregressive modelsCoarsened exact matchingCovariate biasDiabetic peripheral neuropathyHierarchical cluster analysisNeuropathic painPregabalinSleep interference

Identifiers

PMID28728577
PMCPMC5520324

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.